The first domestic new crown oral medicine was included in medical insurance!

The reporter learned from the National Medical Insurance Bureau that in accordance with the relevant provisions of basic medical insurance, in order to better protect the needs of diagnosis and treatment, all medicines that are included in the new coronary pneumonia diagnosis and treatment plan can be temporarily included in the scope of medical insurance payment. On August 9, the National Health and Health Commission has issued a notice to include Azf's fixed slices into the new type of coronary virus pneumonia diagnosis and treatment plan. Therefore, the medical insurance fund can be paid in accordance with regulations when using the drug.

It is understood that Azf's fixed tablet is the treatment of oral small molecular virus pneumonia therapy drugs independently developed by my country. On July 25 this year, in accordance with the relevant provisions of the Drug Management Law, the State Drug Administration has attached conditions to approve the application of Henan Real Biotechnology Co., Ltd. Azf's fixed chip to increase the application for the treatment of new coronary virus pneumonia. The fixed tablet is used to treat adult patients with COVID-19).

The price of Azf's fixed film was also exposed for the first time. Fosun Pharmaceutical said that according to the price of medical insurance networks in various places, Azf's fixed table is priced at 270 yuan per bottle, 35 tablets per bottle, and 1 mg per piece. Compared with the new crown therapy drugs currently on the market, the price of Azf's fixed tablet has the price of Azf's fixed tablet. Larger advantage.

Azf's fixed film is the first approval of my country to have completely independent intellectual property rights and global patent 1.1 type 1.1 anti -new crown pneumonia small molecules oral drugs, which is developed by real biology. In terms of inhibiting the role of new coronal virus, Azf's fixed tablet can inhibit the activity of the new coronal virus. In addition, from the perspective of security, the overall tolerance of Azf's fixed sets is good. The incidence of adverse events has no statistical differences with the placebo group and the risk of the subject.

On August 9, the General Office of the National Health and Health Commission and the Office of the State Administration of Traditional Chinese Medicine issued a notice saying that the medicine was included in the "New Coronatic Virus Pneumonia diagnosis and treatment plan (ninth edition)". According to the diagnosis and treatment plan, Azf's fixed tablet is used to treat adult patients with COVID-19). The amount of usage is swallowed by the entire space, 5mg each time, once a day, the course of treatment is not more than 14 days.

According to the above usage, and each dose, the reporter calculated that patients need to take 5 tablets a day, and the treatment requires 70 tablets for 14 days, that is, the amount of two boxes, the cost of 540 yuan.

Azf's fixed film is a typical "old medicine and new use". On July 20, 2021, the State Drug Administration has attached a condition to approve the use of Azf's fixed tablet with other reverse transcription enzyme inhibitors to treat adult HIV (HIV-1) infection patients with high virus load. On July 25, 2022, the Emergency Conditions of the State Drug Administration approved the real creature Azf fixed tablet to increase the application of new coronary pneumonia treatment indications for the treatment of adult patients of ordinary new coronary virus pneumonia. On the same day, Fosun Pharmaceutical announced a strategic cooperation with real creatures. The two parties will jointly develop and be fixed by the holding subsidiary Fosun pharmaceutical industry.

---

Edit | Zhou Yanmei Responsible | Zhang Xiuli

Source | CCTV News Client Beijing Daily Nanfang Daily

Produced by Guangdong Health Online All -Media Team

- END -